Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx se xxxx x doplňuje xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Sb. x. x. a x. 46/2008 Sb. x. x. x xxxxxxxxx sdělení Ministerstva xxxxxxxxxxxx věcí č. 97/2012 Sb. m. x. x Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 12. listopadu 2012 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx1).
S xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. ledna 2013 x tímto xxxx xxxxxxxxx v platnost x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Přílohy X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx platné xx 1. ledna 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X x její xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu přijatá xxx 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX KODEX
Xxxxxx od 1. xxxxx 2013
Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx za "Specifické xxxxx" kromě xxxxx xx skupin X1, X2, S4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x M3.
|
LÁTKY X XXXXXX ZAKÁZANÉ XXXXX
(PŘI SOUTĚŽI X XXXX SOUTĚŽ)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX LÁTKY
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx stadiu xxxxxxx xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx zakázány.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(a) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx pouze xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)
|
19-noretiocholanolon
|
2. Xxxxxxx anabolické xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx x omezením xxxxx na xx.
| &xxxx;
Xxx xxxxx xxxxxxx této xxxxx: * "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx tělo xxxx xxxxxxxx xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx tělo xxxxxxxxxx xxxxxxxxx.
|
X2. XXXXXXXXX HORMONY, XXXXXXX XXXXXXX X XXXXXXXX LÁTKY
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Látky xxxxxxxxxxx xxxxxxxxxxx (např. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (GH), fibroblastové xxxxxxx faktory (XXXx), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx faktor xxxxxxxx x krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx vláken;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Všichni xxxx-2 xxxxxxxx včetně xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x l-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) a salmeterolu xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxxxxx xxxxx než 1000 xx/xx a přítomnost xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx považována xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx bude xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx sportovec xxxxxxxxx kontrolovanou farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx nižší xxx xxxx xxxxxxx maximum.
X4. HORMONOVÉ X XXXXXXXXXXX MODULÁTORY
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, letrozol, testolacton, xxx ne x xxxxxxxx xxxxx xx xx.
2. Selektivní xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
3. Ostatní antiestrogenní xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx myostatinu, xxx xx s xxxxxxxx xxxxx xx ně.
5. Metabolické xxxxxxxxxx:
x) Insuliny;
x) Xxxxxxxx delta aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x součinnosti s XXXX delta /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. DIURETIKA X XXXXXXX MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. glycerol, nitrožilní xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx x podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx felypressinu pro xxxxx anestézi xxxx xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, chlortalidon, indapamid, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, případně Xxxx Soutěž) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx nebo jinou xxxxxxxxx látkou je xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx xxxxx navíc x xx, xxxxx xxx byla xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací látku.
ZAKÁZANÉ XXXXXX
M1. MANIPULACE X XXXX A XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx systému.
2. Xxxxx zvyšování spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, zahrnující modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), ale xx x omezením pouze xx xx. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.
3. Jakákoliv xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx komponentami fyzikálními xxxx chemickými způsoby.
X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX
Zakázané xx následující:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, ale xx s xxxxxxxx xxxxx na ně.
2. Xxxxxxxxxx xxxxxx x/xxxx injekce xxxx xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx legitimně xxxxxxxxx x průběhu nemocničních xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx zakázáno následující:
1. Transfer nukleových xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx S0 xx S5 x X1 xx M3 xxxxxxxxx xxxx jsou Xxx Xxxxxxx xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- a x-) xxxx xxxxxxxx, x xxxxxxxx derivátů xxxxxxxxx x xxxxxxx xxxxxx místního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx zahrnují:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, fenproporex, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Specifická stimulancia (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, isomethepten, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, oktopamin, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
* Následující xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, nikotin, pipradrol, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx xxxxx.
** Xxxxxxx podání xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx x lokálními anestetiky xxxx xxxxxxxx.
*** Xxxxx je zakázaný xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx v 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx než 10 mikrogramů v 1 xx moči.
***** Pseudoefedrin xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, petidin.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, nitrožilní nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX
|
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Při Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx xxxxxxxx dechovou xxxxxxxx a/nebo rozborem xxxx. Xxxxxxx hodnota xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Letecké xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Vodní xxxxxxxxxx (UIM)
X2. XXXX-XXXXXXXXX
Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x snowboard X-xxxxx x "big xxx"
∙ Střelba (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, bunolol, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. nabyl účinnosti xxxx 20.12.2013.
Právní xxxxxxx č. 98/2013 Xx. m. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx od 20.9.2014.
Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.